Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 44 entries
Sorted by: Best Match Show Resources per page
Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort.

Clinical epidemiology

Jensvoll H, Severinsen MT, Hammerstrøm J, Brækkan SK, Kristensen SR, Cannegieter SC, Blix K, Tjønneland A, Rosendaal FR, Dziewiecka O, Overvad K, Næss IA, Hansen JB.
PMID: 26396546
Clin Epidemiol. 2015 Sep 16;7:401-10. doi: 10.2147/CLEP.S84279. eCollection 2015.

BACKGROUND: Although venous thromboembolism (VTE) is a known common complication in cancer patients, there is limited knowledge on patient-related and cancer-specific risk factors in the general population. The Scandinavian Thrombosis and Cancer (STAC) Cohort was established by merging individual...

Cite
Jensvoll H, Severinsen MT, Hammerstrøm J, et al. Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort. Clin Epidemiol. 2015;7:401-10doi: 10.2147/CLEP.S84279.
Jensvoll, H., Severinsen, M. T., Hammerstrøm, J., Brækkan, S. K., Kristensen, S. R., Cannegieter, S. C., Blix, K., Tjønneland, A., Rosendaal, F. R., Dziewiecka, O., Overvad, K., Næss, I. A., & Hansen, J. B. (2015). Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort. Clinical epidemiology, 7401-10. https://doi.org/10.2147/CLEP.S84279
Jensvoll, Hilde, et al. "Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort." Clinical epidemiology vol. 7 (2015): 401-10. doi: https://doi.org/10.2147/CLEP.S84279
Jensvoll H, Severinsen MT, Hammerstrøm J, Brækkan SK, Kristensen SR, Cannegieter SC, Blix K, Tjønneland A, Rosendaal FR, Dziewiecka O, Overvad K, Næss IA, Hansen JB. Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort. Clin Epidemiol. 2015 Sep 16;7:401-10. doi: 10.2147/CLEP.S84279. eCollection 2015. PMID: 26396546; PMCID: PMC4577261.
Copy Download .nbib Format: NLM
Evaluating Outcomes from an Integrated Health Service for Older Patients.

The Ochsner journal

Severinsen KD, Tufton A, Hannan E, Schwind JS, Schmucker D, Cutler A.
PMID: 26730227
Ochsner J. 2015;15(4):423-8.

BACKGROUND: Hospital-associated disability is the loss of the ability to complete one activity of daily living (ADL), with this decline occurring between the onset of acute illness and discharge from the hospital. Approximately 30% of patients who are >70...

Cite
Severinsen KD, Tufton A, Hannan E, et al. Evaluating Outcomes from an Integrated Health Service for Older Patients. Ochsner J. 2015;15(4):423-8
Severinsen, K. D., Tufton, A., Hannan, E., Schwind, J. S., Schmucker, D., & Cutler, A. (2015). Evaluating Outcomes from an Integrated Health Service for Older Patients. The Ochsner journal, 15(4), 423-8.
Severinsen, Kyle D, et al. "Evaluating Outcomes from an Integrated Health Service for Older Patients." The Ochsner journal vol. 15,4 (2015): 423-8.
Severinsen KD, Tufton A, Hannan E, Schwind JS, Schmucker D, Cutler A. Evaluating Outcomes from an Integrated Health Service for Older Patients. Ochsner J. 2015;15(4):423-8. PMID: 26730227; PMCID: PMC4679304.
Copy Download .nbib Format: NLM
The Inverse Response Law: Theory and Relevance to the Aftermath of Disasters.

International journal of environmental research and public health

Phibbs S, Kenney C, Rivera-Munoz G, Huggins TJ, Severinsen C, Curtis B.
PMID: 29734692
Int J Environ Res Public Health. 2018 May 04;15(5). doi: 10.3390/ijerph15050916.

The Inverse Care Law is principally concerned with the effect of market forces on health care which create inequities in access to health services through privileging individuals who possess the forms of social capital that are valued within health...

Cite
Phibbs S, Kenney C, Rivera-Munoz G, et al. The Inverse Response Law: Theory and Relevance to the Aftermath of Disasters. Int J Environ Res Public Health. 2018;15(5)doi: 10.3390/ijerph15050916.
Phibbs, S., Kenney, C., Rivera-Munoz, G., Huggins, T. J., Severinsen, C., & Curtis, B. (2018). The Inverse Response Law: Theory and Relevance to the Aftermath of Disasters. International journal of environmental research and public health, 15(5), . https://doi.org/10.3390/ijerph15050916
Phibbs, Suzanne, et al. "The Inverse Response Law: Theory and Relevance to the Aftermath of Disasters." International journal of environmental research and public health vol. 15,5 (2018). doi: https://doi.org/10.3390/ijerph15050916
Phibbs S, Kenney C, Rivera-Munoz G, Huggins TJ, Severinsen C, Curtis B. The Inverse Response Law: Theory and Relevance to the Aftermath of Disasters. Int J Environ Res Public Health. 2018 May 04;15(5). doi: 10.3390/ijerph15050916. PMID: 29734692; PMCID: PMC5981955.
Copy Download .nbib Format: NLM
NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study.

Cancer management and research

Østgård LSG, Nørgaard M, Pedersen L, Østgård R, Friis LS, Schöllkopf C, Severinsen MT, Marcher CW, Medeiros BC, Jensen MK.
PMID: 30464604
Cancer Manag Res. 2018 Oct 29;10:5043-5051. doi: 10.2147/CMAR.S165498. eCollection 2018.

BACKGROUND: Most cases of acute leukemia arise without identifiable risk factors. Studies investigating the impact of autoimmune diseases and infections on leukemogenesis have revealed conflicting results. If inflammation increases the risk of acute myeloid leukemia (AML), nonsteroidal anti-inflammatory drug...

Cite
Østgård LSG, Nørgaard M, Pedersen L, et al. NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study. Cancer Manag Res. 2018;10:5043-5051doi: 10.2147/CMAR.S165498.
Østgård, L. S. G., Nørgaard, M., Pedersen, L., Østgård, R., Friis, L. S., Schöllkopf, C., Severinsen, M. T., Marcher, C. W., Medeiros, B. C., & Jensen, M. K. (2018). NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study. Cancer management and research, 105043-5051. https://doi.org/10.2147/CMAR.S165498
Østgård, Lene Sofie Granfeldt, et al. "NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study." Cancer management and research vol. 10 (2018): 5043-5051. doi: https://doi.org/10.2147/CMAR.S165498
Østgård LSG, Nørgaard M, Pedersen L, Østgård R, Friis LS, Schöllkopf C, Severinsen MT, Marcher CW, Medeiros BC, Jensen MK. NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study. Cancer Manag Res. 2018 Oct 29;10:5043-5051. doi: 10.2147/CMAR.S165498. eCollection 2018. PMID: 30464604; PMCID: PMC6214335.
Copy Download .nbib Format: NLM
Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort.

TH open : companion journal to thrombosis and haemostasis

Gade IL, Brækkan SK, Næss IA, Hansen JB, Cannegieter SC, Rosendaal FR, Overvad K, Hindberg K, Hammerstrøm J, Gran OV, Tjønneland A, Severinsen MT, Kristensen SR.
PMID: 31249936
TH Open. 2018 Apr 06;2(2):e131-e138. doi: 10.1055/s-0038-1641678. eCollection 2018 Apr.

The risk of venous thromboembolism (VTE) in patients who survive the first years after a cancer diagnosis after the acute effects of disease and treatment in comparison to a similar background population has been sparsely investigated. The aim of...

Cite
Gade IL, Brækkan SK, Næss IA, et al. Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort. TH Open. 2018;2(2):e131-e138doi: 10.1055/s-0038-1641678.
Gade, I. L., Brækkan, S. K., Næss, I. A., Hansen, J. B., Cannegieter, S. C., Rosendaal, F. R., Overvad, K., Hindberg, K., Hammerstrøm, J., Gran, O. V., Tjønneland, A., Severinsen, M. T., & Kristensen, S. R. (2018). Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort. TH open : companion journal to thrombosis and haemostasis, 2(2), e131-e138. https://doi.org/10.1055/s-0038-1641678
Gade, Inger Lise, et al. "Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort." TH open : companion journal to thrombosis and haemostasis vol. 2,2 (2018): e131-e138. doi: https://doi.org/10.1055/s-0038-1641678
Gade IL, Brækkan SK, Næss IA, Hansen JB, Cannegieter SC, Rosendaal FR, Overvad K, Hindberg K, Hammerstrøm J, Gran OV, Tjønneland A, Severinsen MT, Kristensen SR. Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort. TH Open. 2018 Apr 06;2(2):e131-e138. doi: 10.1055/s-0038-1641678. eCollection 2018 Apr. PMID: 31249936; PMCID: PMC6524868.
Copy Download .nbib Format: NLM
A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia.

Leukemia research

Nørskov KH, Fridthjof K, Kampmann P, Dünweber A, Andersen CL, Renaberg T, Schöllkopf C, Ahmad SA, Schou K, Jensen CF, Møller P, Lundholm BW, Marcher C, Jepsen L, Ørntoft AK, Ommen HB, Andersen L, Behrentzs A, Hasselgren CF, Severinsen M, Grand MK, Jarden M, Møller T, Kjeldsen L.
PMID: 34839055
Leuk Res. 2021 Nov 22;112:106756. doi: 10.1016/j.leukres.2021.106756. Epub 2021 Nov 22.

Technological advances have made it possible to offer home-based chemotherapy to patients without health care professionals being present. Prior studies on effects of home-based treatment lack inclusion of patients with hematologic malignancies. We present data from a multicenter single-arm...

Cite
Nørskov KH, Fridthjof K, Kampmann P, et al. A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia. Leuk Res. 2021;112:106756doi: 10.1016/j.leukres.2021.106756.
Nørskov, K. H., Fridthjof, K., Kampmann, P., Dünweber, A., Andersen, C. L., Renaberg, T., Schöllkopf, C., Ahmad, S. A., Schou, K., Jensen, C. F., Møller, P., Lundholm, B. W., Marcher, C., Jepsen, L., Ørntoft, A. K., Ommen, H. B., Andersen, L., Behrentzs, A., Hasselgren, C. F., Severinsen, M., Grand, M. K., Jarden, M., Møller, T., & Kjeldsen, L. (2021). A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia. Leukemia research, 112106756. https://doi.org/10.1016/j.leukres.2021.106756
Nørskov, Kristina Holmegaard, et al. "A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia." Leukemia research vol. 112 (2021): 106756. doi: https://doi.org/10.1016/j.leukres.2021.106756
Nørskov KH, Fridthjof K, Kampmann P, Dünweber A, Andersen CL, Renaberg T, Schöllkopf C, Ahmad SA, Schou K, Jensen CF, Møller P, Lundholm BW, Marcher C, Jepsen L, Ørntoft AK, Ommen HB, Andersen L, Behrentzs A, Hasselgren CF, Severinsen M, Grand MK, Jarden M, Møller T, Kjeldsen L. A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia. Leuk Res. 2021 Nov 22;112:106756. doi: 10.1016/j.leukres.2021.106756. Epub 2021 Nov 22. PMID: 34839055.
Copy Download .nbib Format: NLM
The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records.

Clinical epidemiology

Lauritsen TB, Nørgaard JM, Grønbæk K, Vallentin AP, Ahmad SA, Hannig LH, Severinsen MT, Adelborg K, Østgård LSG.
PMID: 34163252
Clin Epidemiol. 2021 Jun 14;13:439-451. doi: 10.2147/CLEP.S306857. eCollection 2021.

BACKGROUND: The Danish Myelodysplastic Syndromes Database (DMDSD) comprises nearly all patients diagnosed with myelodysplastic syndromes (MDS) in Denmark since 2010. The DMDSD has not yet been used for epidemiological research and the quality of registered variables remains to be...

Cite
Lauritsen TB, Nørgaard JM, Grønbæk K, et al. The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records. Clin Epidemiol. 2021;13:439-451doi: 10.2147/CLEP.S306857.
Lauritsen, T. B., Nørgaard, J. M., Grønbæk, K., Vallentin, A. P., Ahmad, S. A., Hannig, L. H., Severinsen, M. T., Adelborg, K., & Østgård, L. S. G. (2021). The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records. Clinical epidemiology, 13439-451. https://doi.org/10.2147/CLEP.S306857
Lauritsen, Tine Bichel, et al. "The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records." Clinical epidemiology vol. 13 (2021): 439-451. doi: https://doi.org/10.2147/CLEP.S306857
Lauritsen TB, Nørgaard JM, Grønbæk K, Vallentin AP, Ahmad SA, Hannig LH, Severinsen MT, Adelborg K, Østgård LSG. The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records. Clin Epidemiol. 2021 Jun 14;13:439-451. doi: 10.2147/CLEP.S306857. eCollection 2021. PMID: 34163252; PMCID: PMC8213953.
Copy Download .nbib Format: NLM
Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system.

Future oncology (London, England)

Brøndum RF, Vestergaard AS, Børty L, Vesteghem C, Rytter AS, Nielsen MM, Severinsen MT, Jensen P, Gregersen H, El-Galaly TC, Dybkær K, Ehlers LH, Bøgsted M, Roug AS.
PMID: 34156281
Future Oncol. 2021 Sep;17(25):3331-3341. doi: 10.2217/fon-2021-0189. Epub 2021 Jun 22.

No abstract available.

Cite
Brøndum RF, Vestergaard AS, Børty L, et al. Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system. Future Oncol. 2021;17(25):3331-3341doi: 10.2217/fon-2021-0189.
Brøndum, R. F., Vestergaard, A. S., Børty, L., Vesteghem, C., Rytter, A. S., Nielsen, M. M., Severinsen, M. T., Jensen, P., Gregersen, H., El-Galaly, T. C., Dybkær, K., Ehlers, L. H., Bøgsted, M., & Roug, A. S. (2021). Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system. Future oncology (London, England), 17(25), 3331-3341. https://doi.org/10.2217/fon-2021-0189
Brøndum, Rasmus F, et al. "Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system." Future oncology (London, England) vol. 17,25 (2021): 3331-3341. doi: https://doi.org/10.2217/fon-2021-0189
Brøndum RF, Vestergaard AS, Børty L, Vesteghem C, Rytter AS, Nielsen MM, Severinsen MT, Jensen P, Gregersen H, El-Galaly TC, Dybkær K, Ehlers LH, Bøgsted M, Roug AS. Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system. Future Oncol. 2021 Sep;17(25):3331-3341. doi: 10.2217/fon-2021-0189. Epub 2021 Jun 22. PMID: 34156281.
Copy Download .nbib Format: NLM
Severe Peripheral Neuropathy From Treatment With Arsenic Trioxide in a Patient Suffering From Acute Promyelocytic Leukemia.

Journal of hematology

Helso SN, Roug AS, Mork M, Maksten EF, Severinsen MT.
PMID: 32855758
J Hematol. 2020 Sep;9(3):89-92. doi: 10.14740/jh617. Epub 2020 Aug 14.

Treatment with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) is standard treatment for patients suffering from acute promyelocytic leukemia (APL). Peripheral neuropathy is a common sign of arsenic poisoning but reports of peripheral neuropathy from patients treated with...

Cite
Helso SN, Roug AS, Mork M, et al. Severe Peripheral Neuropathy From Treatment With Arsenic Trioxide in a Patient Suffering From Acute Promyelocytic Leukemia. J Hematol. 2020;9(3):89-92doi: 10.14740/jh617.
Helso, S. N., Roug, A. S., Mork, M., Maksten, E. F., & Severinsen, M. T. (2020). Severe Peripheral Neuropathy From Treatment With Arsenic Trioxide in a Patient Suffering From Acute Promyelocytic Leukemia. Journal of hematology, 9(3), 89-92. https://doi.org/10.14740/jh617
Helso, Soren Niemi, et al. "Severe Peripheral Neuropathy From Treatment With Arsenic Trioxide in a Patient Suffering From Acute Promyelocytic Leukemia." Journal of hematology vol. 9,3 (2020): 89-92. doi: https://doi.org/10.14740/jh617
Helso SN, Roug AS, Mork M, Maksten EF, Severinsen MT. Severe Peripheral Neuropathy From Treatment With Arsenic Trioxide in a Patient Suffering From Acute Promyelocytic Leukemia. J Hematol. 2020 Sep;9(3):89-92. doi: 10.14740/jh617. Epub 2020 Aug 14. PMID: 32855758; PMCID: PMC7430865.
Copy Download .nbib Format: NLM
Synthesis and Basicity Studies of Quinolino[7,8-.

The Journal of organic chemistry

Rowlands GJ, Severinsen RJ, Buchanan JK, Shaffer KJ, Jameson HT, Thennakoon N, Leito I, Lõkov M, Kütt A, Vianello R, Despotović I, Radić N, Plieger PG.
PMID: 32786648
J Org Chem. 2020 Sep 04;85(17):11297-11308. doi: 10.1021/acs.joc.0c01428. Epub 2020 Aug 13.

Quinolino[7,8-

Cite
Rowlands GJ, Severinsen RJ, Buchanan JK, et al. Synthesis and Basicity Studies of Quinolino[7,8-. J Org Chem. 2020;85(17):11297-11308doi: 10.1021/acs.joc.0c01428.
Rowlands, G. J., Severinsen, R. J., Buchanan, J. K., Shaffer, K. J., Jameson, H. T., Thennakoon, N., Leito, I., Lõkov, M., Kütt, A., Vianello, R., Despotović, I., Radić, N., & Plieger, P. G. (2020). Synthesis and Basicity Studies of Quinolino[7,8-. The Journal of organic chemistry, 85(17), 11297-11308. https://doi.org/10.1021/acs.joc.0c01428
Rowlands, Gareth J, et al. "Synthesis and Basicity Studies of Quinolino[7,8-." The Journal of organic chemistry vol. 85,17 (2020): 11297-11308. doi: https://doi.org/10.1021/acs.joc.0c01428
Rowlands GJ, Severinsen RJ, Buchanan JK, Shaffer KJ, Jameson HT, Thennakoon N, Leito I, Lõkov M, Kütt A, Vianello R, Despotović I, Radić N, Plieger PG. Synthesis and Basicity Studies of Quinolino[7,8-. J Org Chem. 2020 Sep 04;85(17):11297-11308. doi: 10.1021/acs.joc.0c01428. Epub 2020 Aug 13. PMID: 32786648.
Copy Download .nbib Format: NLM
A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia.

Leukemia research

Nørskov KH, Fridthjof K, Kampmann P, Dünweber A, Andersen CL, Renaberg T, Schöllkopf C, Ahmad SA, Schou K, Jensen CF, Møller P, Lundholm BW, Marcher C, Jepsen L, Ørntoft AK, Ommen HB, Andersen L, Behrentzs A, Hasselgren CF, Severinsen M, Grand MK, Jarden M, Møller T, Kjeldsen L.
PMID: 34839055
Leuk Res. 2021 Nov 22;112:106756. doi: 10.1016/j.leukres.2021.106756. Epub 2021 Nov 22.

Technological advances have made it possible to offer home-based chemotherapy to patients without health care professionals being present. Prior studies on effects of home-based treatment lack inclusion of patients with hematologic malignancies. We present data from a multicenter single-arm...

Cite
Nørskov KH, Fridthjof K, Kampmann P, et al. A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia. Leuk Res. 2021;112:106756doi: 10.1016/j.leukres.2021.106756.
Nørskov, K. H., Fridthjof, K., Kampmann, P., Dünweber, A., Andersen, C. L., Renaberg, T., Schöllkopf, C., Ahmad, S. A., Schou, K., Jensen, C. F., Møller, P., Lundholm, B. W., Marcher, C., Jepsen, L., Ørntoft, A. K., Ommen, H. B., Andersen, L., Behrentzs, A., Hasselgren, C. F., Severinsen, M., Grand, M. K., Jarden, M., Møller, T., & Kjeldsen, L. (2021). A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia. Leukemia research, 112106756. https://doi.org/10.1016/j.leukres.2021.106756
Nørskov, Kristina Holmegaard, et al. "A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia." Leukemia research vol. 112 (2021): 106756. doi: https://doi.org/10.1016/j.leukres.2021.106756
Nørskov KH, Fridthjof K, Kampmann P, Dünweber A, Andersen CL, Renaberg T, Schöllkopf C, Ahmad SA, Schou K, Jensen CF, Møller P, Lundholm BW, Marcher C, Jepsen L, Ørntoft AK, Ommen HB, Andersen L, Behrentzs A, Hasselgren CF, Severinsen M, Grand MK, Jarden M, Møller T, Kjeldsen L. A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia. Leuk Res. 2021 Nov 22;112:106756. doi: 10.1016/j.leukres.2021.106756. Epub 2021 Nov 22. PMID: 34839055.
Copy Download .nbib Format: NLM
Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark.

Cancers

Bødker JS, Sønderkær M, Vesteghem C, Schmitz A, Brøndum RF, Sommer M, Rytter AS, Nielsen MM, Madsen J, Jensen P, Pedersen IS, Grubach L, Severinsen MT, Roug AS, El-Galaly TC, Dybkær K, Bøgsted M.
PMID: 32013121
Cancers (Basel). 2020 Jan 29;12(2). doi: 10.3390/cancers12020312.

Within recent years, many precision cancer medicine initiatives have been developed. Most of these have focused on solid cancers, while the potential of precision medicine for patients with hematological malignancies, especially in the relapse situation, are less elucidated. Here,...

Cite
Bødker JS, Sønderkær M, Vesteghem C, et al. Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark. Cancers (Basel). 2020;12(2)doi: 10.3390/cancers12020312.
Bødker, J. S., Sønderkær, M., Vesteghem, C., Schmitz, A., Brøndum, R. F., Sommer, M., Rytter, A. S., Nielsen, M. M., Madsen, J., Jensen, P., Pedersen, I. S., Grubach, L., Severinsen, M. T., Roug, A. S., El-Galaly, T. C., Dybkær, K., & Bøgsted, M. (2020). Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark. Cancers, 12(2), . https://doi.org/10.3390/cancers12020312
Bødker, Julie S, et al. "Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark." Cancers vol. 12,2 (2020). doi: https://doi.org/10.3390/cancers12020312
Bødker JS, Sønderkær M, Vesteghem C, Schmitz A, Brøndum RF, Sommer M, Rytter AS, Nielsen MM, Madsen J, Jensen P, Pedersen IS, Grubach L, Severinsen MT, Roug AS, El-Galaly TC, Dybkær K, Bøgsted M. Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark. Cancers (Basel). 2020 Jan 29;12(2). doi: 10.3390/cancers12020312. PMID: 32013121; PMCID: PMC7073219.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 44 entries